The essential role of infection-detection technologies for malaria elimination and eradication

Trends in Parasitology

Volumn 30, Issue 5, 2014, Pages 259-266

  Tietje, Kathleen ^a   Hawkins, Kenneth ^a   Clerk, Christine ^a   Ebels, Kelly ^a   McGray, Sarah ^a   Crudder, Chris ^a   Okell, Lucy ^b   LaBarre, Paul ^a  

^a PATH   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Active surveillance; Asymptomatic; Elimination; Low density; Malaria

Indexed keywords

DIAGNOSTIC TEST; EPIDEMIC; ERADICATION THERAPY; HUMAN; INFECTION CONTROL; MALARIA; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE; PLASMODIUM VIVAX; PREVALENCE; REVIEW; TECHNOLOGY;

ACTIVE SURVEILLANCE; ASYMPTOMATIC; ELIMINATION; LOW DENSITY; MALARIA;

DIAGNOSTIC TECHNIQUES AND PROCEDURES; DISEASE ERADICATION; HUMANS; MALARIA;

EID: 84899472807     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.03.003     Document Type: Review

References (78)

1. WHO World Malaria Report 2013 2013, World Health Organization (WHO).
2. Cohen J.M., et al. Malaria resurgence: a systematic review and assessment of its causes. Malar. J. 2012, 11:122.
3. WHO Malaria Elimination: A Field Manual for Low and Moderate Endemic Countries 2007, World Health Organization (WHO).
4. Foundation for Innovative New Diagnostics, et al. Malaria Rapid Diagnostic Test Performance: Results of WHO Product Testing of Malaria RDTs: Round 4 (2012) 2012, Foundation for Innovative New Diagnostics/World Health Organization (WHO).
5. A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med. 2011, 8:1-10. The malERA Consultative Group on Diagnoses and Diagnostics.
6. Cotter C., et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 2013, 382:900-911.
7. Bottius E., et al. Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction. Trans. R. Soc. Trop. Med. Hyg. 1996, 90:15-19.
8. Laishram D.D., et al. The complexities of malaria disease manifestations with a focus on asymptomatic malaria. Malar. J. 2012, 11:29.
9. WHO Global Malaria Control and Elimination: Report of a Technical Review 2008, World Health Organization (WHO).
10. Cohen J.M., et al. How absolute is zero? An evaluation of historical and current definitions of malaria elimination. Malar. J. 2010, 9:213.
11. Pampana E. A Textbook of Malaria Eradication 1963, Oxford University Press.
12. Campbell C.C., Steketee R.W. Malaria in Africa can be eliminated. Am. J. Trop. Med. Hyg. 2011, 85:584-585.
13. Chiyaka C., et al. Infectious disease. The stability of malaria elimination. Science 2013, 339:909-910.
14. Mendis K., et al. From malaria control to eradication: the WHO perspective. Trop. Med. Int. Health 2009, 14:802-809.
15. Bousema J., et al. Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya. Malar. J. 2004, 3:18.
16. Harris I., et al. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar. J. 2010, 9:254.
17. Okell L.C., et al. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat. Commun. 2012, 3:1-9.
18. Young M.D., Hardman N.F. The infectivity of native malarias in South Carolina to Anopheles quadrimaculatus. Am. J. Trop. Med. Hyg. 1948, 28:303-311.
19. Alves F.P., et al. Asymptomatic carriers of Plasmodium spp. as infection source for malaria vector mosquitoes in the Brazilian Amazon. J. Med. Entomol. 2005, 42:777-779.
20. Jeffrey G.M., Eyles D.E. Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. Am. J. Trop. Med. Hyg. 1955, 4:781-789.
21. Delley V., et al. What does a single determination of malaria parasite density mean? A longitudinal survey in Mali. Trop. Med. Int. Health 2000, 5:404-412.
22. O'Meara W.P., et al. Sources of variability in determining malaria parasite density by microscopy. Am. J. Trop. Med. Hyg. 2005, 73:593-598.
23. Farnert A., et al. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. Am. J. Trop. Med. Hyg. 1997, 56:538-547.
24. Di Perri G., et al. The ParaSight(TM)-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 1997, 91:403-405.
25. Kodisinghe H.M., et al. The ParaSight(TM)-F dipstick test as a routine diagnostic tool for malaria in Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 1997, 91:398-402.
26. Van den Eede P., et al. Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study. PLoS ONE 2011, 6:e16257.
27. Incardona S., et al. Large-scale malaria survey in Cambodia: novel insights on species distribution and risk factors. Malar. J. 2007, 6:37.
28. Littrell M., et al. Case investigation and reactive case detection for malaria elimination in northern Senegal. Malar. J. 2013, 12:331.
29. Bousema T., et al. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012, 9:e1001165.
30. Bejon P., et al. Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med. 2010, 7:e1000304.
31. Roper C., et al. Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Am. J. Trop. Med. Hyg. 1996, 54:325-331.
32. Kim J.Y., et al. Comparison of rapid diagnostic tests for the detection of Plasmodium vivax malaria in South Korea. PLoS ONE 2013, 8:e64353.
33. Ministry of Health (MOH)/Solomon Islands Vector Borne Disease Control Program Malaria Information System Database Query 2012, Solomon Islands MOH.
34. Manuel Ramos J., et al. Change in epidemiology of malaria infections in a rural area in Ethiopia. J. Travel Med. 2005, 12:155-156.
35. Carlton J.M., et al. Why is Plasmodium vivax a neglected tropical disease?. PLoS Negl. Trop. Dis. 2011, 5:e1160.
36. Mueller I., et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 2009, 9:555-566.
37. John G.K., et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar. J. 2012, 11:280.
38. Collins W.E., et al. A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax. Am. J. Trop. Med. Hyg. 2004, 70:638-641.
39. Tjitra E., et al. Field evaluation of the ICT Malaria P.f/P.v Immunochromatographic Test for detection of Plasmodium falciparum and Plasmodium vivax in patients with presumptive clinical diagnosis of malaria in eastern Indonesia. J. Clin. Microbiol. 1999, 37:2412-2417.
40. Wells T.N., et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010, 26:145-151.
41. Betuela I., et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J. Infect. Dis. 2012, 206:1771-1780.
42. Cappellini M.D., Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008, 371:64-74.
43. Howes R.E., et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012, 9:e1001339.
44. Baird J.K. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 2013, 26:36-57.
45. Beutler E., et al. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am. J. Trop. Med. Hyg. 2007, 77:779-789.
46. Lee N., et al. Identification of optimal epitopes for Plasmodium falciparum rapid diagnostic tests that target histidine-rich proteins 2 and 3. J. Clin. Microbiol. 2012, 50:1397-1405.
47. Baker J., et al. Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based rapid diagnostic tests. J. Infect. Dis. 2005, 192:870-877.
48. Lee N., et al. Effect of sequence variation in Plasmodium falciparum histidine-rich protein 2 on binding of specific monoclonal antibodies: implications for rapid diagnostic tests for malaria. J. Clin. Microbiol. 2006, 44:2773-2778.
49. Baker J., et al. Global sequence variation in the histidine-rich proteins 2 and 3 of Plasmodium falciparum: implications for the performance of malaria rapid diagnostic tests. Malar. J. 2010, 9:129.
50. Gamboa D., et al. A large proportion of P. falciparum isolates in the Amazon region of Peru lack Pfhrp2 and Pfhrp3: implications for malaria rapid diagnostic tests. PLoS ONE 2010, 5:e8091.
51. Maltha J., et al. Rapid diagnostic tests for malaria diagnosis in the Peruvian Amazon: impact of pfhrp2 gene deletions and cross-reactions. PLoS ONE 2012, 7:e43094.
52. Koita O.A., et al. False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the Hrp2 gene. Am. J. Trop. Med. Hyg. 2012, 86:194-198.
53. Kumar N., et al. Genetic deletion of HRP2 and HRP3 in Indian Plasmodium falciparum population and false negative malaria rapid diagnostic test. Acta Trop. 2013, 125:119-121.
54. Houze S., et al. Combined deletions of Pfhrp2 and Pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test. J. Clin. Microbiol. 2011, 49:2694-2696.
55. Wurtz N., et al. Pfhrp2 and Pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. Malar. J. 2013, 12:34.
56. Udhayakumar V., Barnwell J. Molecular profile and survey of HRP2 and HRP3 genetic deletions in South America. Proceedings of the AMI/RAVREDA Annual Meeting (9 April 2013; Lima, Peru) 2013, Amazon Network for the Surveillance of Antimalarial Drug Resistance (AMI/RAVREDA).
57. WHO Guidelines for the Treatment of Malaria. (2nd edn) 2010, World Health Organization (WHO).
58. McMorrow M.L., et al. Malaria rapid diagnostic tests in elimination settings-can they find the last parasite?. Clin. Microbiol. Infect. 2011, 17:1624-1631.
59. Sturrock H.J., et al. Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med. 2013, 10:e1001467.
60. Sturrock H.J., et al. Reactive case detection for malaria elimination: real life experience from an ongoing program in Swaziland. PLoS ONE 2013, 8:e63830.
61. WHO Disease Surveillance for Malaria Elimination: An Operational Manual 2012, World Health Organization. http://www.who.int/malaria/publications/atoz/9789241503334/en/index.html.
62. Gueye C.S., et al. Active case detection for malaria elimination: a survey among Asia Pacific countries. Malar. J. 2013, 12:358.
63. Tatarsky A., et al. Preventing the reintroduction of malaria in Mauritius: a programmatic and financial assessment. PLoS ONE 2011, 6:e23832.
64. Malaria Consortium Cambodia: Identification Algorithm for Asymptomatic Malaria in Migrants 2013, Malaria Consortium. http://www.malariaconsortium.org/resources/publications/209/cambodia-identification-algorithm-for-asymptomatic-malaria-in-migrants.
65. Yangzom T., et al. Malaria control in Bhutan: case study of a country embarking on elimination. Malar. J. 2012, 11:9.
66. Asia Pacific Malaria Elimination Network (APMEN) Hotspots and hot-pops. Proceedings of the APMEN Vivax Working Group Meeting (2 March 2013, Bali) 2013, University of California San Francisco, Malaria Elimination Initiative.
67. Sanders K., et al. Active case detection for malaria elimination: a confusion of acronyms and definitions. Malar. Chemo. Contr. Elim. 2012, 1:235552.
68. Sutcliffe C.G., et al. Reduced risk of malaria parasitemia following household screening and treatment: a cross-sectional and longitudinal cohort study. PLoS ONE 2012, 7:e31396.
69. Stresman G.H., et al. A method of active case detection to target reservoirs of asymptomatic malaria and gametocyte carriers in a rural area in Southern Province, Zambia. Malar. J. 2010, 9:265.
70. Hoyer S., et al. Focused screening and treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS ONE 2012, 7:e45797.
71. Yekutiel P. Problems of epidemiology in malaria eradication. Bull. World Health Organ. 1960, 22:669-683.
72. Yip K. Malaria eradication: the Taiwan experience. Parassitologia 2000, 42:117-126.
73. WHO Global Plan for Artemisinin Resistance Containment (GPARC) 2011, World Health Organization. http://www.who.int/malaria/publications/atoz/9789241500838/en/index.html.
74. Crowell V., et al. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malar. J. 2013, 12:4.
75. Mosha J.F., et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar. J. 2013, 12:221.
76. Okell L.C., et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE 2011, 6:e20179.
77. U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry and Review Staff Target Product Profile-A Strategic Development Process Tool 2007, CDER. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080593.pdf.
78. Tebbey P.W., Rink C. Target product profile: a renaissance for its definition and use. J. Med. Market. 2009, 9:301-307.